Dimerix's (ASX:DXB) cash outflows are expected to materially reduce in the current quarter as recruitment, the company's largest component of clinical trial expenditure, has been completed, according to a Jan. 30 report by Euroz Harlteys.

The company earlier said it had reached its full recruitment target, enrolling a total of 309 patients, and recorded cash outflows of AU$11.1 million in the December 2025 quarter.

Upon receipt of approval from the US Food and Drug Administration (FDA), the company can proceed with an interim analysis of drug candidate DMX-200 in the ACTION3 trial for patients with focal segmental glomerulosclerosis, in the subsequent weeks, Euroz said.

This may support the accelerated approval application and potential US commercialization of DMX-200 in the second half of the year, Euroz noted.

If the US FDA does not approve the analysis, Dimerix would be required to complete a study of the drug, delaying both approval and the commercialization by about two years, Euroz added.

Euroz maintained the company's speculative buy rating but lowered its price target to AU$1.65 from AU$1.68.